FDA Expands Xarelto Indication to Treat, Reduce Recurrence of Blood Clots

A A
The FDA has approved new indications for Janssen Pharmaceuticals’ Xarelto to treat deep vein thrombosis (DVT) or pulmonary embolism (PE) and to reduce the risk of recurrent DVT and PE following initial treatment.

To View This Article:

Login

Subscribe To Drug Industry Daily